LymphomaArchives
Effectiveness of axicabtagene ciloleucel versus conventional treatments as first-line therapy for high-risk large B-cell lymphoma: an external comparator study
Lymphoma 5 min.
Large B-cell lymphoma (LBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for up to 40% of all NHLs, and immunochemotherapy regimens with an anti-CD20 monoclonal antibody such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or dose-adjusted R-EPOCH (rituximab,...
Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany
Lymphoma 7 min.
Hematological malignancies include a heterogeneous group of lymphomas, multiple myelomas, and leukemias [1]. They differ according to cell type, clinical and molecular characteristics, prognosis, and treatment options [2, 3]. Follicular (FL) and diffuse large B-cell lymphomas (DLBCLs) are the most common...
Severe central airway obstruction caused by primary endobronchial B-cell lymphoma: three case reports and literature review
Lymphoma 3 min.
Central airway obstruction (CAO), defined as an occlusion exceeding 50% of the trachea, mainstem bronchi, or lobar bronchi, is associated with severe clinical manifestations and a high mortality rate. It may result from extrinsic compression by surrounding structures, direct invasion from adjacent tumors,...
CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence
Lymphoma 1 min.
CD19-directed Chimeric Antigen Receptor T-Cell therapy has revolutionized treatment for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Since the approval of axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel—CAR-T has offered high response rates and durable...
